Announcement PDF ImpediMed Limited Suite 31C, 12-18 Tryon Rd Lindfield NSW 2070 Australia E: investorrelations@impedimed.com W : impedimed.com 15 October 2026 Companies Announcements Office Australian Securities Exchange Notice of Annual General Meeting and Voting Form Attached is a Notice of Meeting and Voting Form in respect of the Annual General Meeting for ImpediMed Limited (ImpediMed) (ASX:IPD) which is being held on Wednesday, 18 November 2026 at 11.00am AEDT. Approved for release by the Board of ImpediMed Limited. For more information, contact Leanne Ralph, Company Secretary, at leanne.ralph@bellev.com.au Page | 1 ImpediMed Limited ACN 089 705 144 Notice of Annual General Meeting Wednesday, 18 November 2026 11.00am (AEDT) Page | 2 Chair’s message 15 October 2026 Dear ImpediMed Shareholder, On behalf of the Board, I am pleased to invite you to attend the 2026 Annual General Meeting (AGM) of ImpediMed Limited, which will be held on Wednesday, 18 November 2026 commencing at 11.00am (AEDT) at the offices of Clifford Chance, Level 24, Brookfield Place, 10 Carrington Street, Sydney NSW 2000. The meeting will also be held via an audio webcast to enable those shareholders who are unable to attend in person, to participate in the AGM. We do, however, encourage you to attend the meeting in person if you are able to. You can participate in the AGM through the online platform at https://meetings.openbriefing.com/IPD26. Details on how to join online are set out in the attached Notice of Meeting and in the Virtual Meeting Online Guide which are available on our website at https://investors.impedimed.com/corporate-governance. Please read the Notice of Meeting (including the Explanatory Memorandum) (which can be found at https://investors.impedimed.com/corporate-governance), and the Voting Form and consider how to vote on each resolution related to the items of business of the AGM. Subject to the abstentions noted in the Explanatory Memorandum, the Directors of ImpediMed recommend that Shareholders vote in favour of all resolutions. If you are unable to attend the AGM, I encourage you to vote online no later than 11.00am (AEDT) on Monday, 16 November 2026. Shareholders will have the opportunity to submit questions or make comments prior to the AGM or during the AGM, and details of how to do this are outlined in the attached Notice of Meeting. I also encourage you to read our 2026 Annual Report which provides a detailed overview of business performance last year, which can be found at https://investors.impedimed.com/annual-reports. Thank you for your continued support of ImpediMed. I look forward to the opportunity to provide you with a progress update and to hear your views at our AGM. Yours sincerely, Christine Emmanuel-Donnelly Chair Page | 3 Participation in the AGM The Annual General Meeting (AGM) of ImpediMed Limited (ImpediMed or Company) will be held on Wednesday, 18 November 2026 commencing at 11.00am (AEDT). Shareholders can participate in the AGM in the following ways: Before the AGM AGM Notice of Meeting Vote or appoint proxy Ask a question or make a comment Access online at https://investors.impedimed.com/corp orate-governance. Return the hard copy Voting Form or vote online at https://au.investorcentre.mpms.mufg .com/ To be valid, your Direct Vote or proxy appointment must be received by 11.00am (AEDT) on Monday, 16 November 2026 Submit questions online or https://au.investorcentre.mpms.mufg .com/ by 5.00pm (AEDT) on Wednesday, 11 November 2026 Request a hard copy of the Notice of Meeting by phone +61 1300 554 474 or email communications@cm.mpms.mufg.com At the AGM Attend the AGM in person The AGM will be held at the offices of Clifford Chance, Level 24, Brookfield Place, 10 Carrington Street, Sydney NSW 2000. Shareholders, proxyholders, body corporate representatives or attorneys attending the meeting in person will be able to ask questions or make a comment and vote at the meeting. Join online Vote online Ask a question or make a comment online • Enter https://meetings.openbriefing.com/I PD26 into a web browser • Enter your name, phone number, email and company name (if applicable) and select ‘Continue’ to register • If you are a shareholder, enter your SRN/HIN and postcode • If you are a proxy, enter the code that MUFG will email to you 12 hours before the AGM Only Shareholders, proxyholders, body corporate representatives or attorneys can vote. • Once you have registered via the portal, your voting card will appear on your screen • Voting will open at the start of the AGM • Select ‘Get a Voting Card’ to vote Only Shareholders, proxyholders, body corporate representatives or attorneys can ask questions or make comments. • Click on the ‘Ask a Question’ box at the top or the bottom of the webpage • Select the Resolution to which your question relates from the ‘Regarding’ menu and type your question or comment • Questions will be read aloud to the AGM Please refer to the Virtual Meeting Online Guide at https://investors.impedimed.com/corporate-governance for further details about attending via the online portal. If you need assistance, please call +61 1800 990 363. If you would like to receive a printed copy of this Notice or any future Notices, please contact the Share Registry on +61 1300 554 474. Page | 4 Notice of Annual General Meeting Notice is hereby given that the Annual General Meeting (AGM) of Shareholders of ImpediMed Limited (Company or ImpediMed) will be held on Wednesday, 18 November 2026 at 11.00am (AEDT) at the offices of Clifford Chance, Level 24, Brookfield Place, 10 Carrington Street, Sydney NSW 2000, and via an audio webcast (Meeting). The Explanatory Memorandum accompanying this Notice provides additional information on matters to be considered at the Meeting. The Explanatory Memorandum, Voting Procedures and the Voting Form comprise part of this Notice. Items of business __________________________________________________________________________________ Item 1: Financial statements and reports To receive and consider the Financial Report, the Directors’ Report and the Auditor’s Report for the Company for the financial year ended 30 June 2026. All Shareholders can view the Annual Report, which contains the Financial Report for the year ended 30 June 2026, at https://investors.impedimed.com/annual-reports. Item 2: Remuneration Report To consider and, if thought fit, pass the following as an advisory resolution of the Company: “To adopt the Remuneration Report for the year ended 30 June 2026.” Notes: (i) In accordance with section 250R of the Corporations Act, the vote on this resolution will be advisory only and will not bind the Directors or the Company. (ii) A voting exclusion applies to this resolution (see Explanatory Memorandum for details). Item 3: Re-election of Ms Janelle Delaney To consider and, if thought fit, pass the following as an ordinary resolution of the Company: “That Ms Janelle Delaney, being a Director who is retiring in accordance with clause 16 of the Company’s Constitution and Listing Rule 14.4, and being eligible, offers herself for re-election, be re- elected as a director of the Company.” Page | 5 Item 4: Re-election of Ms Fiona Bones To consider and, if thought fit, pass the following as an ordinary resolution of the Company: “That Ms Fiona Bones, being a Director who is retiring in accordance with clause 16 of the Company’s Constitution and Listing Rule 14.4, and being eligible, offers herself for re-election, be re-elected as a director of the Company.” Item 5: Approval to issue securities under the ImpediMed Employee Incentive Plan To consider, and if thought fit, pass the following as an ordinary resolution of the Company: “That, for the purposes of Part 2D.2 of the Corporations Act (including sections 200B, 200C and 200E), Listing Rule 7.2, Exception 13 and for all other purposes, approval is given to the ImpediMed Employee Incentive Plan and the US Sub-Plan (in each case, as amended) and the issue of securities under the ImpediMed Employee Incentive Plan, on the terms and conditions set out in the Explanatory Memorandum.” Note: A voting exclusion applies to this resolution (see Explanatory Memorandum for details). Item 6: Grant of 109,794,161 Performance Rights to Mr Erik Anderson, Chief Executive Officer and Managing Director, under the ImpediMed Employee Incentive Plan To consider and, if thought fit, pass the following as an ordinary resolution of the Company: “That for the purposes of Listing Rule 10.14 and for all other purposes, approval is given to the grant and issue of 109,794,161 Performance Rights to Mr Erik Anderson, the Chief Executive Officer and Managing Director of the Company, and the subsequent issue of Shares on the vesting of those Performance Rights, under the ImpediMed Employee Incentive Plan and on the terms and conditions set out in the Explanatory Memorandum.” Note: A voting exclusion applies to this resolution (see Explanatory Memorandum for details). Item 7: Approval of Chief Executive Officer and Managing Director termination benefits To consider and, if thought fit, pass the following as an ordinary resolution of the Company: “That for the purposes of Part 2D.2 of the Corporations Act (including sections 200B, 200C and 200E), Listing Rule 10.19 and for all other purposes, approval is given to the provision of benefits to Mr Erik Anderson, the Chief Executive Officer and Managing Director of the Company, in connection with Mr Anderson ceasing to hold a managerial or executive office with the Company or a Related Body Corporate, or in connection with the transfer of the whole or any part of the undertaking or property of the Company or a Related Body Corporate, on the terms and conditions set out in the Explanatory Memorandum." Note: A voting exclusion applies to this resolution (see Explanatory Memorandum for details). Page | 6 Item 8: Change of Company name and Constitution To consider and, if thought fit, pass the following as a special resolution of the Company: “That, for the purposes of sections 157(1)(a) and 136(2) of the Corporations Act and for all other purposes, approval is given for the Company to change name from ImpediMed Limited to SOZOHealth Holdings Limited, and all references to the Company’s name within the Constitution be amended to reflect the Company’s new name, in each case effective from the date that the Australian Securities and Investments Commission updates its register to reflect the new name.” Page | 7 Voting Procedures All resolutions will be by poll _________________________________________________________________________ In accordance with clause 10.9 of the Company’s Constitution (Constitution), the Chair intends to demand a poll on each of the resolutions proposed at the Meeting. Each resolution considered at the Meeting will therefore be conducted by a poll. The Chair considers voting by poll to be in the interests of Shareholders as a whole and is a way to ensure the views of as many Shareholders as possible are represented at the Meeting. Entitlement to vote _________________________________________________________________________ The Directors have determined pursuant to regulation 7.11.37 of the Corporations Regulations 2001 (Cth) that the persons eligible to vote at the Meeting are those who are registered Shareholders of the Company as at 7.00pm (AEDT) on Monday, 16 November 2026 (Entitlement Time). This means that if you are not the registered holder of a Share in the Company at the Entitlement Time, you will not be entitled to vote at the Meeting. How to vote – before the AGM _________________________________________________________________________ Direct vote – using the Voting Form In accordance with clause 12.3 of the Constitution, Shareholders are able to vote directly on resolutions considered at the Meeting at any time between the date of this Notice of Meeting and 11.00am (AEDT) on Monday, 16 November 2026 by returning the hard copy Voting Form or by voting online (further details below). If you lodge a direct vote, you are voting directly and are not appointing a third party, such as a proxy, to act on your behalf. The ImpediMed Direct Voting Regulations governing direct voting are available on the ImpediMed website at https://investors.impedimed.com/corporate-governance. By submitting a direct vote, you agree to be bound by the ImpediMed Direct Voting Regulations. Appointment of Proxy A Shareholder who is entitled to vote at this Meeting is entitled to appoint not more than two proxies to vote in place of the Shareholder. If the Shareholder appoints two proxies, the Shareholder may specify the proportion or number of votes each proxy is entitled to exercise. If no proportion or number of votes is specified, each proxy may exercise half of the Shareholder’s votes. If the specified proportion or number of votes exceeds that which the Shareholder is entitled to, each proxy may exercise half of the Shareholder’s votes. Any fractions of votes brought about by the apportionment of votes to a proxy will be disregarded. A proxy need not be a Shareholder of the Company. A body corporate appointed as a Shareholder’s proxy may appoint a representative to exercise any of the powers the body may exercise as a proxy at the Meeting. The representative should bring to the Meeting evidence of his or her appointment, including any authority under which the appointment is signed, unless it has previously been given to the Company. Subject to the specific proxy provisions applying to Items 2, 5, 6 and 7 (see the Explanatory Memorandum): - If a Shareholder has not directed their proxy on how to vote on Items 2, 5, 6 and 7 the proxy may vote as the proxy determines; and - If a Shareholder appoints the Chair of the Meeting as proxy and does not direct the Chair how to vote on an item of business, the Chair will vote in accordance with her voting intention as stated in this Notice of Meeting. Page | 8 Submitting your Voting Form To be valid, a Voting Form must be received by the Company in the manner set out in this Notice. The Chair’s decision on the validity of a direct vote, vote cast by a proxy or vote cast in person, is conclusive and the Company reserves the right to declare invalid any Voting Form not received in this manner. For your proxy or direct vote prior to the AGM to be effective, your completed, signed and lodged Voting Form (together with the relevant original power of attorney or a certified copy of the proxy signed by an attorney) must be received by the Company’s Share Registry, MUFG Corporate Markets (AU) Limited, no later than 11.00am (AEDT) on Monday, 16 November 2026 (Proxy Deadline). After this time, you will still be able to lodge your vote during the AGM by attending the Meeting in person. Voting forms may be submitted in one of the following ways: Online: Via the Company’s Share Registry at https://au.investorcentre.mpms.mufg.com/. You will need your Securityholder Reference Number (SRN) or Holding Identification Number (HIN) and postcode for your shareholding. Mobile device: Using a mobile device by scanning the QR code on the back of the Voting Form. You will also need your SRN or HIN and postcode for your shareholding. By post: MUFG Corporate Markets (AU) Limited, Locked Bag A14, Sydney South NSW 1235. Please allow sufficient time so that it reaches MUFG Corporate Markets (AU) Limited by the Proxy Deadline. By fax: (02) 9287 0309 (within Australia), +61 2 9287 0309 (from outside Australia). By hand delivery: MUFG Corporate Markets (AU) Limited at Parramatta Square, Level 22, Tower 6, 10 Darcy Street, Parramatta NSW Voting Forms and Powers of Attorney must be received by the Proxy Deadline. Power of Attorney A proxy appointment and the original power of attorney (if any) under which the proxy appointment is signed (or a certified copy of that power of attorney or other authority) must be received by the Company no later than the Proxy Deadline. Corporate Representatives A body corporate which is a Shareholder, or which has been appointed as a proxy, is entitled to appoint any person to act as its representative at the Meeting. The appointment of the representative must comply with the requirements under section 250D of the Corporations Act. The representative must bring to the AGM a properly executed letter or other document confirming its authority to act as the body corporate’s representative. A ‘Certificate of Appointment of a Corporate Representative’ form can be obtained from ImpediMed’s share registry or online at https://au.investorcentre.mpms.mufg.com (under Resources then Forms). How to vote – during the AGM _________________________________________________________________________ Attending in person Shareholders, proxyholders, body corporate representatives or attorneys attending the meeting in person will be able to vote and ask questions or make comments, at the meeting. Using the Online Platform Shareholders can vote directly using the online platform https://meetings.openbriefing.com/IPD26 at any time between the commencement of the AGM (11.00am AEDT on Wednesday, 18 November 2026) and the closure of voting as announced by the Chair during the AGM. Shareholders will be able to cast their vote using the electronic voting card received after clicking the ‘Get a Voting Card’ button. If you have more than one shareholding, continue to click on ‘Get a Voting Card’ to receive cards for each of your holdings. Shareholders can then choose to vote at any time during the Meeting. A change can be made to your vote at any time while voting remains open. Once you submit your voting card, you will be unable to change it. Any cards not submitted by the close of voting will be automatically submitted. Page | 9 More information about how to use the online platform, including how to vote and ask questions online during the AGM, is available in the Virtual Meeting Online Guide, which has been lodged with the ASX and is available at our website at https://investors.impedimed.com/corporate-governance. If you intend to use the online platform, we recommend that you check to ensure the online platform works on your device before the AGM. Proxy Voting by the Chair _________________________________________________________________________ For Items 2, 5, 6 and 7 where the Chair is appointed as a Shareholder’s proxy and that Shareholder has not specified the way in which the Chair is to vote on these items, the Shareholder is expressly authorising the Chair to vote in accordance with the Chair’s voting intentions for this item of business, even though Items 2, 5, 6 and 7 are connected directly or indirectly with the remuneration of Key Management Personnel (KMP). The Chair intends to vote all undirected proxies in favour of all the resolutions in the Notice of Meeting, including Items 2, 5, 6 and 7. Questions and Comments from Shareholders _________________________________________________________________________ Before the AGM Shareholders can submit questions in advance of the AGM via the Share Registry website at https://au.investorcentre.mpms.mufg.com/. To allow time to collate questions and prepare answers, please submit any questions by 5.00pm (AEDT) on Wednesday, 11 November 2026. Questions will be collated, and the Chair and/or Chief Executive Officer will seek to address as many of the more frequently raised topics as possible during the AGM. Please note that individual responses will not be sent to Shareholders. During the AGM Shareholders, proxyholders, body corporate representatives or attorneys attending the meeting in person or online will be able to ask questions or make comments during the Meeting, as described earlier in this Notice. BY ORDER OF THE BOARD Leanne Ralph Company Secretary 15 October 2026 Page | 10 Explanatory Memorandum This Explanatory Memorandum has been prepared for the information of Shareholders of the Company in relation to the business to be conducted at the Company’s AGM to be held at 11.00am (AEDT) on Wednesday, 18 November 2026. The purpose of this Explanatory Memorandum is to provide Shareholders with information that is reasonably required to decide how to vote on the resolutions contained in the Notice. Subject to the abstentions noted below in respect of each resolution, the Board recommends that Shareholders vote in favour of all resolutions. The Chair of the Meeting intends to vote all available undirected proxies in favour of each resolution. The resolutions in Items 3 - 7 are ordinary resolutions, which require a simple majority of votes cast by Shareholders entitled to vote on the resolution. The resolution in Item 2, relating to the Remuneration Report, is advisory and does not bind the Directors or the Company. The resolution in Item 8 is a special resolution. _________________________________________________________________________ Item 1: Financial statements and reports As required by section 317 of the Corporations Act the Financial Report, Directors’ Report and Auditor’s Report of the Company for the most recent financial year will be presented at the Meeting. The Financial Report contains the financial statements of ImpediMed Limited. There is no requirement for a formal resolution on this Item. The Chair of the Meeting will allow a reasonable opportunity at the Meeting for Shareholders to ask questions about or make comments on the management of the Company and to ask questions about, or make comments on, the Annual Report. Shareholders will also be given a reasonable opportunity at the Meeting to ask the Company’s auditor, Ernst & Young (EY), questions about the Auditor’s Report, the conduct of its audit of the Company’s Financial Report for the financial year ended 30 June 2026, the preparation and content of the Auditor’s Report, the accounting policies adopted by the Company in its preparation of the financial statements and the independence of EY in relation to the conduct of the audit. Shareholders may submit written questions or comments to the Company in relation to the above matters, and the way to do this is outlined earlier in this Notice. Item 2: Remuneration Report The Company has prepared a Remuneration Report for consideration and adoption by Shareholders. The Remuneration Report on pages 25-38 of the Company’s Annual Report for the year ended 30 June 2026 sets out the remuneration policies of the Company and reports on the remuneration arrangements and outcomes for KMP, including the directors and executives of the Company. The 2026 Annual Report is available at https://investors.impedimed.com/annual-reports. As provided by section 250R(3) of the Corporations Act, the resolution on this item of business is advisory only and does not bind the Board or the Company. The Board will consider the outcome of the vote and comments from Shareholders when considering the Company’s remuneration policies. Voting exclusion The Company will disregard any votes cast on Item 2 by, or on behalf of: (a) any member or a former member of the KMP whose remuneration details are disclosed in the Company’s 2026 Remuneration Report, or (b) a Closely Related Party of such a KMP, unless the vote is cast by a person as proxy for a person entitled to vote in accordance with a direction on the Voting Form. Page | 11 This restriction on voting undirected proxies does not apply to the Chair of the Meeting acting as proxy for a person entitled to vote on Item 2 because the Company’s proxy appointment expressly authorised the Chair of the Meeting to exercise undirected proxies even though the Item is connected with the remuneration of a member of the Company’s KMP. What this means for Shareholders: If you intend to appoint a member of the KMP (such as one of the Directors) as your proxy, please ensure that you direct them how to vote on the proposed resolution in Item 2. If you intend to appoint the Chair of the Meeting as your proxy, you can direct the Chair how to vote by marking the boxes for Item 2 (for example, if you wish to vote for, against or abstain from voting), or you can choose not to mark any of the boxes for Item 2 and give the Chair your express authority to vote your undirected proxy (in which case the Chair will vote in favour of this item of business). Board recommendation The Board recommends that Shareholders vote FOR Item 2. Item 3 – 4: Re-election of Directors In accordance with the Company’s Constitution and the Listing Rules, an election of Directors must be held at each annual general meeting. Clause 16.1 of the Constitution states that one-third of all Directors (excluding the Managing Director and Directors appointed during the year by the Board) must retire at every annual general meeting and are eligible to stand for re-election. The Directors to retire pursuant to clause 16.1 of the Constitution are the Directors (other than the Managing Director) who have held office the longest since being appointed or last being elected. In the case where Directors were elected on the same day, the Directors to retire are determined by agreement between the Directors, or a ballot. Further, ASX Listing Rule 14.4 states that a director must not hold office without re-election past the third annual general meeting following the director's appointment or three years, whichever is longer. Item 3: Re-election of Ms Janelle Delaney Ms Janelle Delaney has elected to retire and offer herself for re-election at this Meeting. Ms Delaney was last elected by shareholders on 19 November 2024. She currently serves as a member of the Audit and Risk Management Committee, Remuneration, People and Culture Committee and the Nomination Committee. Ms Delaney has over three decades of extensive IT experience covering all facets from sales through software development, project/program delivery and business management. As a partner at IBM Consulting, she is responsible for the quality of project delivery across IBM Consulting Asia Pacific’s portfolio of several thousand projects and across all solutions (including digital transformation, AI, package implementations, application management services). Prior to submitting herself for re-election, Ms Delaney confirmed that she would continue to have sufficient time to properly fulfil her director duties for the Company. Having had regard to the ASX Corporate Governance Principles and Recommendations (4th edition) (ASX Principles), the Board considers Ms Delaney to be an independent director. Board recommendation The Board (with Ms Delaney abstaining) supports the election of Ms Delaney and recommends that Shareholders vote FOR Ms Delaney’s re-election as a Director of the Company. Page | 12 Item 4: Re-election of Ms Fiona Bones Ms Fiona Bones has elected to retire and offer herself for re-election at this Meeting. Ms Bones was last elected by shareholders on 19 November 2024. She is the Chair of the Audit and Risk Management Committee and a member of the Nomination Committee. Ms Bones currently serves as Vice President of Finance, International Controller at Google where she has worked for more than two decades. She is a Fellow of the Association of Chartered Certified Accountants, U.K and Ireland, and brings ImpediMed a wealth of global experience in finance, corporate governance and systems transformation. At Google, Ms Bones manages a team of 260 across 23 jurisdictions. She holds the distinction of being Google’s first accountant for EMEA (Europe, Middle East and Africa), its first financial controller for Asia Pacific, and its first international controller for all territories outside the US. Prior to Google, Ms Bones served in finance roles with Micros Systems and Siebel Systems. Prior to submitting herself for re-election, Ms Bones confirmed that she would continue to have sufficient time to properly fulfil her director duties for the Company. Having had regard to the ASX Principles, the Board considers Ms Bones to be an independent director. Board recommendation The Board (with Ms Bones abstaining) supports the re-election of Ms Fiona Bones and recommends that Shareholders vote FOR Ms Bones’ re-election as a Director of the Company. Item 5: Approval to issue securities under the ImpediMed Employee Incentive Plan Background The Company established an Employee Incentive Plan (EIP) in September 2014 under which employees may be eligible to receive Shares, Performance Rights or Options. A US Sub-Plan to the EIP was also established as a means of providing incentives to employees who are residents or citizens of the United States. The purpose of the EIP (and the US Sub-Plan) is to align the interests of employees with those of the Company and Shareholders, and to attract, retain, and motivate employees. Listing Rule 7.1 allows the Company to issue a maximum of 15% of its capital in any 12-month period without requiring Shareholder approval. Listing Rule 7.2 allows certain issues of securities to be excluded from the calculation of the number of securities issued in the 12-month period, including under exception 13(b), where an issue is made under an employee incentive plan, if within three years before the date of issue, the issue of securities under terms of the plan are approved by Shareholders. Shareholders last approved the issue of securities under the EIP for the purposes of exception 13(b) of Listing Rule 7.2 at the AGM held on 19 November 2024 (2024 AGM). Exception 13(b) will cease to be available if there is a material change in the terms of the EIP (including the US Sub-Plan) from the terms set out in the 2024 AGM notice of meeting. On 8 October 2026 the Board of ImpediMed exercised its powers under rule 13.1 of the EIP to make the following amendments to the US Sub-Plan: • to increase the 'Appendix A Share Limit' from 100,000,000 shares to 350,000,000 shares and to increase the 'ISO Limit' from 100,000,000 shares to 350,000,000 shares; • to provide that restricted share units and performance share units